GSK’s anaemia drug gets FDA advisory committee support for patients on dialysis
A final decision for daprodustat by the FDA is expected by 1 February 2023
Read Moreby Fleur Jeffries | Oct 31, 2022 | News | 0
A final decision for daprodustat by the FDA is expected by 1 February 2023
Read Moreby Lucy Parsons | Nov 8, 2021 | News | 0
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anaemia due to chronic kidney disease
Read Moreby Lucy Parsons | Aug 12, 2021 | News | 0
FDA has requested an additional clinical trial on the safety of roxadustat
Read Moreby Selina McKee | Jun 29, 2020 | News | 0
BMS’ Reblozyl is the first and only erythroid maturation agent approved in the EU
Read Moreby Anna Smith | Jul 25, 2019 | News | 0
The trial met its primary efficacy endpoint of a mean change in haemoglobin from baseline averaged over weeks 23-27.
Read Moreby Selina McKee | Dec 6, 2018 | News | 0
Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
Read Moreby Selina McKee | Sep 20, 2018 | News | 0
A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints.
Read Moreby Selina McKee | May 26, 2017 | News | 0
Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications.
Read Moreby Selina McKee | Nov 25, 2016 | News | 0
GlaxoSmithKline has begun Phase III development of daprodustat, testing its potential as a treatment for anaemia associated with chronic kidney disease (CKD).
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479